Systemic Immune-Inflammation Index Is Superior to Neutrophil to Lymphocyte Ratio in Prognostic Assessment of Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

Cong Jiang,Yuanxi Huang,Yubo Lu,Shiyuan Zhang,Pierfrancesco Franco

doi:10.1155/2020/7961568

Cong Jiang, Yuanxi Huang + Show 3 more

Open Access

https://doi.org/10.1155/2020/7961568

Copy DOI

Journal: BioMed research international	Publication Date: Dec 18, 2020
Citations: 25	License type: CC BY 4.0

Affiliation: Harbin Medical University

Abstract

Results SII, NLR, and PLR did not define patient groups with distinct clinicopathological characteristics. SII, NLR, and PLR cut-off values were 547, 2.13, and 88.23, as determined by ROC analysis; the corresponding areas under the curve (AUCs) were 0.625, 0.555, and 0.571, respectively. Cox regression models identified SII as independently associated with OS. Patients with low SII had prolonged OS (65 vs. 41 months, P = 0.017, HR: 3.24, 95% CI: 1.23-8.55). In the Z test, the difference in AUC between SII and NLR was statistically significant (Z = 2.721, 95% CI: 0.0194-0.119, P = 0.0065). Conclusion Our study suggests that the pretreatment SII value is significantly correlated with OS in breast cancer patients undergoing NAC and that the prognostic utility of SII is superior to that of NLR and PLR.

Highlights

Breast cancer is the most frequently diagnosed cancer in women and is the leading cause of female cancer death [1]
Clinicopathologic Characteristics of all Breast Cancer Patients Divided by systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR)
Two hundred and forty-nine breast cancer patients were classified by SII, NLR, and PLR

Summary

Introduction

Breast cancer is the most frequently diagnosed cancer in women and is the leading cause of female cancer death [1]. We explore the impact of SII in a cohort of 249 breast cancer patients receiving neoadjuvant chemotherapy (NAC), investigating the prognostic value of SII, neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR). Receiver operating characteristic (ROC) analysis was used to determine the optimal cut-off value for patient classification by SII, NLR, and PLR. SII, NLR, and PLR did not define patient groups with distinct clinicopathological characteristics. SII, NLR, and PLR cut-off values were 547, 2.13, and 88.23, as determined by ROC analysis; the corresponding areas under the curve (AUCs) were 0.625, 0.555, and 0.571, respectively.

Objectives

Methods

Results

Conclusion